Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of advanced non-small cell lung cancer: A phase II study of the Italian oncology group for clinical research (goirc)

MLA

Boni, C., et al. “Gemcitabine, Ifosfamide, Cisplatin (GIP) for the Treatment of Advanced Non-Small Cell Lung Cancer: A Phase II Study of the Italian Oncology Group for Clinical Research (Goirc).” International Journal of Cancer, vol. 87, no. 5, Sept. 2000, pp. 724–27. EBSCOhost, https://doi.org/10.1002/1097-0215(20000901)87:5<724::AID-IJC15>3.0.CO;2-N.

APA

Boni, C., Bisagni, G., Savoldi, L., Moretti, G., Rondini, E., Sassi, M., Zadro, A., Pas, T. D., Franciosi, V., Pazzola, A., Vignoli, R., Banzi, M. C., & Pajetta, V. (2000). Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of advanced non-small cell lung cancer: A phase II study of the Italian oncology group for clinical research (goirc). International Journal of Cancer, 87(5), 724–727. https://doi.org/10.1002/1097-0215(20000901)87:5<724::AID-IJC15>3.0.CO;2-N

Chicago

Boni, C., G. Bisagni, L. Savoldi, G. Moretti, E. Rondini, M. Sassi, A. Zadro, et al. 2000. “Gemcitabine, Ifosfamide, Cisplatin (GIP) for the Treatment of Advanced Non-Small Cell Lung Cancer: A Phase II Study of the Italian Oncology Group for Clinical Research (Goirc).” International Journal of Cancer 87 (5): 724–27. doi:10.1002/1097-0215(20000901)87:5<724::AID-IJC15>3.0.CO;2-N.